Company profile
Petros Pharmaceuticals, Inc.
NASDAQ: PTPI · Healthcare · Drug Manufacturers - Specialty & Generic
#704 of 1,418 Healthcare companies by revenue31st-percentile growth
EA Score
47DFH 67DQ 23GM 48SS 20
v0.1 · 65/100 weight · provisional
↑ return on equity, return on assets · ↓ workforce scale, disclosure history
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
$1.9M
Employees
3
as of 2026-08-28
Market cap
$169.5k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$5.1M$5.1M2024
Net income$1.9M$1.9M2025
Operating income-$4.6M-$4.6M2025
Total assets$5.2M$5.2M2025
Liabilities$2.3M$2.3M2025
Equity$2.9M$2.9M2025
Revenue trend
FY2021 – FY2024 · USD
FY21
FY21
FY22
FY23
FY24
Revenue by segment
Filed disclosures · FY2024
By product
Medical Devices100%
By geography
UNITED STATES79%
Non-US21%
The read
What is Petros Pharmaceuticals, Inc.’s revenue?
Petros Pharmaceuticals, Inc. booked $5.1M in FY2024 revenue, contracting 12% year over year — slower than 69% of Healthcare companies we track, at a 37.4% net margin.
Peers · Healthcare
Plus Therapeutics, Inc.38DZeo ScientifiX, Inc.43DRadiko Holdings Corp——Regenerative Medical Technology Group Inc.36DWellbeing Digital Sciences Inc.——Ensysce Biosciences, Inc.31DNeighbors
New York →Key facts
CEOFady Boctor
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersNew York City, NY
ExchangeNASDAQ: PTPI
Employees3
IPO date2020-12-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.